The distribution of antioxidative and repair gene polymorphisms in MM patients and controls and risk of MM
| Polymorphism | Genotype | MM patients | Controls | Unadjusted risk | Adjusted by age | Adjusted by smoking | Adjusted by abestos exposure | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N (%) | N (%) | OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | |||
| CC | 98 (62.0) | 82 (73.9) | ||||||||||
| NQO1 rs1800566 missing data for 10 patients | CT | 57 (36.1) | 27 (24.3) | 1.73 | 0.043 | 1.63 | 0.103 | 1.88 | 0.037 | 1.72 | 0.124 | |
| TT | 3 (1.9) | 2 (1.8) | (1.02–2.96) | (0.91–2.95) | (1.04–3.41) | (0.83–3.57) | ||||||
| CC | 79 (50.0) | 70 (57.4) | ||||||||||
| CAT rs1001179 | CT | 64 (40.5) | 47 (38.5) | 1.35 | 0.220 | 1.21 | 0.484 | 1.47 | 0.159 | 1.45 | 0.288 | |
| TT | 15 (9.5) | 5 (4.1) | (0.84–2.17) | (0.71–2.05) | (0.86–2.51) | (0.73–2.88) | ||||||
| CC | 44 (27.7) | 31 (25.8) | ||||||||||
| SOD2 rs4880 missing data for 2 patients | CT | 81 (50.9) | 52 (43.3) | 0.89 | 0.661 | 0.76 | 0.371 | 0.95 | 0.857 | 0.81 | 0.578 | |
| TT | 31 (19.5) | 37 (30.8) | (0.52–1.52) | (0.41–1.39) | (0.52–1.73) | (0.38–1.73) | ||||||
| CC | 99 (62.3) | 82 (70.1) | ||||||||||
| hOGG1 rs1052133 missing data for 4 patients | CG | 52 (32.7) | 32 (27.4) | 1.37 | 0.225 | 1.42 | 0.232 | 1.36 | 0.286 | 1.77 | 0.125 | |
| GG | 6 (3.8) | 3 (2.6) | (0.82–2.29) | (0.80–0.51) | (0.77–2.41) | (0.85–3.66) | ||||||
Clinical characteristics of MM patients and controls
| Controls (n = 122) | MM patients (n = 159) | Test | p | |
|---|---|---|---|---|
| Gender N (%) | ||||
| Male | 88 (72.1) | 123 (77.4) | ||
| Female | 34 (27.9) | 36 (22.6) | χ2 = 1.008 | 0.315 |
| Age (years), median (range) | 54 (48–60.3) | 65 (57–72) | U = 4392.000 | < 0.001 |
| No. of smokers data missing for 7 MM patients | 13 (10.7) | 80 (52.6) | χ2 = 53.185 | < 0.001 |
| Asbestos exposure data missing for 8 MM patients | ||||
| No | 0 (0.0) | 25 (16.6) | ||
| Yes | 122 (100.0) | 126 (83.4) | ||
| Asbestos exposure data available for all controls and 64 MM patients | ||||
| Low | 96 (78.7) | 22 (34.4) | χ2 = 35.941 | < 0.001 |
| Medium | 11 (9.0) | 21 (32.8) | ||
| High | 15 (12.3) | 21 (32.8) | ||
| Asbestos exposure data available for all controls and 64 MM patients | ||||
| Low | 96 (78.7) | 22 (34.4) | χ2 = 35.451 | < 0.001 |
| Medium and high | 26 (21.3) | 42 (65.6) |
Gene-gene interactions between rs1800566 NAD(P)H quinone dehydrogenase 1 (NQO1), rs1001179 catalase (CAT), rs4880 superoxide dismutase 2 (SOD2), and rs1052133 human 8-oxoguanine glycosylase 1 (hOGG1)
| Gene 1 | Gene 2 | Interaction | |||||
|---|---|---|---|---|---|---|---|
| Genotypes | OR (95% CI) | p | Genotypes | OR (95% CI) | p | OR (95% CI) | p |
| NQO1 rs1800566 CT+TT | 1.73 | 0.043 | hOGG1 rs1052133 | 1.37 | 0.225 | 1.22 | 0.75 |
| VS.CC | (1.02–2.96) | CG+GG VS.CC | (0.82–2.29) | (0.36–4.13) | |||
| CAT rs1001179 | 1.35 | 0.220 | hOGG1 rs1052133 | 1.37 | 0.225 | 0.27 | 0.014 |
| CT+TT VS.CC | (0.84-2.17) | CG+GG VS.CC | (0.82–2.29) | (0.10–0.77) | |||
| SOD2 rs4880 | 0.89 | 0.661 | hOGG1 rs1052133 | 1.37 | 0.225 | 0.78 | 0.669 |
| CT+TT VS.CC | (0.52–1.52) | CG + GG VS.CC | (0.82–2.29) | (0.25–2.43) |
The influence of interactions between the investigated polymorphisms and asbestos exposure on risk of malignant mesothelioma
| Polymorphism | OR | CI (95%) | p |
|---|---|---|---|
| NQO1 rs1800566 | 1.56 | 0.35–6.86 | 0.560 |
| CAT rs1001179 | 1.57 | 0.39–6.29 | 0.522 |
| SOD2 rs4880 | 1.13 | 0.24–5.18 | 0.880 |
| hOGG1 rs1052133 | 0.50 | 0.12–2.14 | 0.352 |